Results 1 to 10 of about 8,127 (167)

Ribociclib and Palbociclib Are Safe and Effective for Treating Metastatic Breast Cancer: A Retrospective Study [PDF]

Cancer Reports
Background Cyclin‐dependent kinase (CDK) 4/6 inhibitors are standard for treating hormone receptor‐positive metastatic breast cancer when combined with endocrine therapy. However, comparisons of first‐line treatments are scarce.
Cheng‐Wei Chou, Yi‐Hung Lo, Chia‐I. Wei, Chiann‐Yi Hsu, Chih‐Chiang Hung, Yen‐Dun Tzeng, Chia‐Hua Liu   +6 more
doaj   +4 more sources

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

Breast, 2022
Background: Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect
Stefano Fogli
exaly   +3 more sources

Physiologically-Based Pharmacokinetics of Ribociclib Drug–Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer [PDF]

Pharmaceuticals
Background: Ribociclib, initially approved for HR+/HER2− advanced breast cancer (ABC) at a 600 mg dose, was recently approved for HR+/HER2− early breast cancer (EBC) at a 400 mg dose based on the NATALEE trial.
Yan Ji, Felix Huth, Craig Wang, Hilmar Schiller, Francois Pierre Combes, John Crown, Peter A. Fasching, Juan Pablo Zarate, Michael Untch   +8 more
doaj   +2 more sources

Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome

Journal of Advanced Research
Introduction: Overwhelming neutrophil activation and oxidative stress significantly contribute to acute respiratory distress syndrome (ARDS) pathogenesis.
Po-Jen Chen, Yung-Fong Tsai, Tsong-Long Hwang   +2 more
exaly   +3 more sources

Immune-Mediated Hepatotoxicity Associated With Ribociclib: A Multipatient Case Series and Management Strategy [PDF]

Case Reports in Oncological Medicine
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), when combined with endocrine therapy, have significantly transformed the management of hormone receptor-positive, HER2-negative metastatic breast cancer.
Jemma Buchalter, Helen O'Donovan, Emmet Jordan, Zita Galvin, Janice M. Walshe   +4 more
doaj   +2 more sources

Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review

Current Problems in Cancer: Case Reports, 2023
Introduction: The phase-3 MONALEESA-2, -3 and -7 randomized trials showed benefit of CDK4/6 inhibitor, ribociclib, in women with advanced-stage breast cancer. However, ribociclib-induced acute kidney injury (AKI) was not addressed in these studies.
Maissoune Hajir, Ramiz Abu-Hijlih, Areej Abu Sheikha, Kholoud Alqasem, Hikmat Abdel-Razeq   +4 more
doaj   +1 more source

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

Breast, 2023
Purpose: This phase II study evaluated the impact of adding ribociclib to maintenance endocrine therapy (ET) treatment of physicians’ choice following the first palliative chemotherapy in pre- and post-menopausal women with hormone receptor positive (HR+)
Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, Nader Hirmas, Kristina Lübbe, Mark-Oliver Zahn, Marcus Schmidt, Carsten Denkert, Ralf Lorenz, Volkmar Müller, Dirk-Michael Zahm, Christoph Mundhenke, Stefan Bauer, Marc Thill, Peter Seropian, Natalie Filmann, Sibylle Loibl   +16 more
doaj   +1 more source

Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells

Frontiers in Pharmacology, 2022
The efficacy of cancer chemotherapy can be attenuated or abrogated by multidrug resistance (MDR) in cancer cells. In this study, we determined the effect of the CDK4/6 inhibitor, ribociclib (or LEE011), on P-glycoprotein (P-gp)-mediated MDR in the human ...
Lei Zhang, Lei Zhang, Lei Zhang, Biwei Ye, Biwei Ye, Yunfeng Lin, Yunfeng Lin, Yi-Dong Li, Jing-Quan Wang, Zhuo Chen, Zhuo Chen, Feng-Feng Ping, Zhe-Sheng Chen   +12 more
doaj   +1 more source

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma

Frontiers in Oncology, 2022
BackgroundRecent clinical trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in human lung adenocarcinoma (LUAD) have not achieved satisfactory results.
Yuan Ke, Cheng-Gong Liao, Zheng-Qing Zhao, Xiao-Min Li, Rong-Jie Lin, Long Yang, He-Long Zhang, Ling-Min Kong   +7 more
doaj   +1 more source

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?

Medicina, 2023
Background and Objectives: This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer managed with
Hatice Odabas, Akif Dogan, Melike Ozcelik, Sedat Yildirim, Ugur Ozkerim, Nedim Turan, Mahmut Emre Yildirim, Mahmut Gumus   +7 more
doaj   +1 more source